We are acting on our purpose to defeat serious chronic diseases by expanding our commitment in areas of high unmet need, including metabolic dysfunction-associated steatohepatitis (MASH).
MASH is also known as nonalcoholic steatohepatitis (NASH).
This is a disease that impacts a growing number of people worldwide, and we welcome you to learn more about its causes, symptoms, and how to improve liver health, while also discovering our research and development efforts to help address the unmet medical need in this disease area.
It can be difficult to understand the differences within the spectrum metabolic dysfunction-associated steatotic liver disease (MASLD), also known as non-alcoholic fatty liver disease (NAFLD)
MASLD is an umbrella term for conditions caused by the build-up of extra fat in the liver that is not caused by alcohol intake. As fatty liver disease progresses, the liver can become inflamed (hepatitis) and damaged, which can lead to fibrosis, or scarring of the liver. When people with MASLD reach this stage it is known as metabolic dysfunction-associated steatohepatitis (MASH), also known as nonalcoholic steatohepatitis (NASH), which is the most severe form of MASLD.
After years of damage due to fibrosis, MASH can lead to cirrhosis, which is severe scarring of the liver that can lead to further complications such as loss of liver function, liver failure and liver cancer.
The exact cause of MASLD and MASH are not known but it is well understood that obesity, type 2 diabetes or pre-diabetes, high levels of ‘bad’ (LDL) cholesterol and metabolic syndrome are risk factors that make people more likely to develop these conditions.
With the rising prevalence of obesity and type 2 diabetes, both strong risk factors for MASH, there is a growing number of people living with this serious chronic disease today.
MASH is known as a ‘silent disease’ because it has few or no symptoms, especially in its early stages. People with MASH usually report feeling non-specific symptoms that can easily be mistaken for other conditions. These symptoms may include:
- Abdominal pain, usually in the upper right side
- Back pain
- Fatigue
- Weakness
Because symptoms are often non-specific, it can be challenging to recognise and diagnose MASH. Confirming a MASH diagnosis will often require a variety of tests, including blood tests, ultrasounds, and a liver biopsy.
There are limited treatment options available for MASH. Following a healthy diet and maintaining a healthy weight is essential to managing this disease. Most people diagnosed with early-stage non-alcoholic fatty liver disease will not develop serious complications, if managed properly.
If you have MASH, it is important that you work with your doctor to come up with a personalised plan to implement lifestyle modifications and losing weight, if needed.
We are leveraging our expertise in obesity and type 2 diabetes with
an ambition to develop new treatment options that can reduce – or even
reverse – liver damage in people living with MASH. We are also
supporting the advancement of non-invasive diagnostic tests to help
address challenges in screening, diagnosing and monitoring prognosis
of MASH.
Global Liver Institute. The language of NASH. Accessed August 29, 2023. https://globalliver.org/wp-content/uploads/2022/06/GLI_TheLanguageofNASH_270820.pdf
Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328-357.
Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018;67(1):123-133.
Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73-84.
Tesfay M, Goldkamp WJ, Neuschwander-Tetri BA. NASH: The Emerging Most Common Form of Chronic Liver Disease. Mo Med. 2018;115(3):225-229.
European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388-1402.
Banini BA, Sanyal AJ. Nonalcoholic Fatty Liver Disease: Epidemiology, Pathogenesis, Natural History, Diagnosis, and Current Treatment Options. Clin Med Insights Ther. 2016;8:75-84.
Neuschwander-Tetri BA. Non-alcoholic fatty liver disease. BMC Med. 2017;15(1):45.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Symptoms & causes of NAFLD & NASH. Accessed September 5, 2023. https://www.niddk.nih.gov/health-information/liver-disease/nafld-nash/symptoms-causes
National Health System (NHS). Non-alcoholic fatty liver disease (NAFLD). Updated January 13, 2022. Accessed September 5, 2023. https://www.nhs.uk/conditions/non-alcoholic-fatty-liver-disease/
Rinella ME. Nonalcoholic fatty liver disease: a systematic review [published correction appears in JAMA. 2015 Oct 13;314(14):1521]. JAMA. 2015;313(22):2263-2273.
Hallsworth K, Adams LA. Lifestyle modification in NAFLD/NASH: Facts and figures. JHEP Rep. 2019;1(6):468-479.